Zanubrutinib in Treating Waldenström Macroglobulinemia | TCRM
B-cell development, survival, and expansion is critically dependent on normally functioning and tightly regulated B-cell receptor (BCR) signaling pathways. Key mediators of the BCR pathway include the proximal kinases - Bruton tyrosine kinase (BTK), phosphatidyl inositol 3 kinase (PI3K), and spleen tyrosine kinase (SYK).
Conclusion: Even though zanubrutinib has been the third and last BTK inhibitor to currently penetrate the market for B-cell lymphoproliferative malignancies, we highlight the emergence of zanubrutinib as a key player in the forefront of the therapeutic landscape in WM.